FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.
Breast cancer survivors
Women under 45
Women over 45
Men with breast cancer
Metastatic breast cancer
Triple negative breast cancer
BRCA mutation carriers
Her2+ breast cancer
Special populations: breast cancer patients who have had or will have chemotherapy
Many people report memory or concentration problems, commonly known as “chemobrain,” during and after cancer treatment. New research shows that for some breast cancer patients these issues continue 6 months after treatment. Documentation of this well-known effect is a crucial first step in developing ways to limit and treat it. (02/02/17)
Understanding “chemobrain.” Researchers wanted to see whether chemotherapy-treated breast cancer patients experience memory and concentration issues, and to begin mapping out the course of this effect.
This study attempted to determine the percentage of breast cancer patients who experience cognitive issues after receiving chemotherapy and how long it lasts, so that health care providers can help patients cope with this effect.
This study suggests that a large number of breast cancer patients who undergo chemotherapy may experience more cognitive difficulties, such as forgetfulness and problems with concentration, than people who are not treated with chemotherapy. This “chemobrain” effect can continue up to 6 months after chemotherapy has been completed. More work needs to be done to understand why this occurs and to identify ways to help patients who experience these difficulties. Patients should talk to their health care providers about this and any other symptoms they have after chemotherapy.
The same article was also covered by the Chicago Tribune
Medical News Today
Researchers are beginning to study cancer-related cognitive impairment, commonly referred to as “chemobrain,” in patients with breast cancer. Early studies were small, included different patient populations (for example, patients with different cancers and treatments), could not be applied to a broad population, or did not study the patients for a long period. Michelle Janelsins and colleagues from the University of Rochester Medical Center and other institutions published work in the Journal of Clinical Oncology in December 2016 describing their efforts to try to understand breast cancer patients’ cognitive difficulties after chemotherapy.
Do breast cancer patients experience cognitive difficulties after undergoing chemotherapy?
This study included 581 women from the research base of the National Cancer Institute Community Oncology Research Program (NCORP) at the University of Rochester. The data represented women who:
The study also included 364 women without cancer who were also recruited by the NCORP. This population included friends and family of the study participants and people who had no relationship with patients in the study.
All participants took the FACT-Cog survey, which addresses the following general areas:
Patients took this survey before chemotherapy, within four weeks of receiving chemotherapy, and six months after chemotherapy. Non-cancer patients were surveyed during the same period.
The follow up period of this study was only six months, so it is not known if these symptoms linger even longer in some patients. However, to address this limitation, the researchers report that they are currently observing a small group of breast cancer patients and people without cancer for two years post treatment.
Additionally, in this study breast cancer patients undergoing chemotherapy were compared to women who did not have cancer, so it not clear whether the memory issues are caused by the stress of facing cancer and its treatment in general or something specific to chemotherapy. Additionally, more work needs to be done to understand how anxiety, depression and other factors affect cognitive function in this population.
This study suggests that nearly half of breast cancer patients who undergo chemotherapy treatment experience cognitive difficulties (“chemobrain”), with just over one-third of patients reporting symptoms even 6 months after treatment. More work needs to be done to understand why these patients experience “chemobrain,” if this is a long-term effect, and potential ways to prevent “chemobrain” or to help patients who experience it. Meanwhile, patients should discuss any cognitive problems or other symptoms they experience after chemotherapy with their health care providers.
Share your thoughts on this XRAYS article by taking our brief survey
Janelsins MC, Heckler CE, Peppone LJ, et al. “Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide Multicenter, Prospective Longitudinal Study.” Journal of Clinical Oncology. Published online first on December 27, 2016.
FORCE Information: Breast Cancer Treatment
FORCE Information: Hereditary Cancer Treatment Options
FORCE Information: Memory Changes